Non Alcoholic Fatty Liver Disease Stocks List

Symbol	Grade	Name	% Change
BLTE	A	Belite Bio, Inc.	4.94
GNFT	A	GENFIT S.A.	0.51
AKRO	A	Akero Therapeutics, Inc.	4.87
PLRX	A	Pliant Therapeutics, Inc.	3.20
VKTX	A	Viking Therapeutics, Inc.	0.47
GYRE	B	Gyre Therapeutics, Inc.	1.19
SGMT	C	Sagimet Biosciences Inc.	3.50
IVA	C	Inventiva S.A.	3.38
ETNB	D	89bio, Inc.	17.48
TERN	D	Terns Pharmaceuticals, Inc.	1.17

Symbol	Grade	Name	Weight
OZEM	D	Roundhill GLP-1 & Weight Loss ETF	5.83
BBC	B	Virtus LifeSci Biotech Clinical Trials ETF	5.31
SURI	A	Simplify Exchange Traded Funds Simplify Propel Opportunities ETF	4.68
ADPV	B	Adaptiv Select ETF	3.9
ULTY	B	YieldMax Ultra Option Income Strategy ETF	3.22

Compare ETFs

Compare BBC to ADPV Compare BBC to SURI Compare SURI to ULTY

Date	Stock	Title
Nov 1	ETNB	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Nov 1	VKTX	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Oct 31	VKTX	This High-Flying Stock Just Became a Better Buy
Oct 30	IVA	Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Oct 30	VKTX	Viking Therapeutics CFO Cashes Out: $10M in Shares Sold Amidst Stock Surge
Oct 29	ETNB	89bio: Surviving A Competitive Space - For Now
Oct 29	VKTX	Pfizer Unveils Its Next Black Box In Obesity. It's Taking On Amgen.
Oct 29	SGMT	Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Oct 28	VKTX	Viking Therapeutics: Lots Of Positives
Oct 28	VKTX	Viking Therapeutics to Highlight Clinical Data from VK2735 Obesity Program in Presentations at ObesityWeek® 2024
Oct 27	VKTX	Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?

Non Alcoholic Fatty Liver Disease: Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver, causing inflammation and damage. It is the most common form of liver disease in the United States, affecting up to 25% of the population. NAFLD is closely linked to obesity, diabetes, and high cholesterol, and can lead to serious complications such as cirrhosis and liver cancer. Treatment typically involves lifestyle changes such as weight loss, exercise, and a healthy diet.